Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jan 12;25(1):85-88.
doi: 10.1093/ijnp/pyab078.

Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant

Manish Kumar Jha  1
Affiliations
Editorial

Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant

Manish Kumar Jha. Int J Neuropsychopharmacol. .

Abstract

There is a large unmet need for effective treatment of major depressive disorder (MDD), an often chronic/recurrent disorder that affects 1 in 5 adults during their lifetime in the United States. Clinicians and individuals with MDD often rely on augmentation approaches given the low rate of remission with the initial antidepressant treatment. Therefore, the report by Savitz and colleagues on the safety and efficacy of seltorexant is of great interest because it provides initial evidence for the antidepressant potential of drugs targeting orexin neurotransmission. Findings of this study suggest that seltorexant 20 mg is more effective than placebo, especially in individuals with moderate or insomnia symptoms at baseline. Given that insomnia is a common feature of depression, orexin 2 receptor antagonists may serve as important new treatment alternatives for people with MDD.

Keywords: Antidepressant; Orexin; Seltorexant; insomnia; major depressive disorder.

PubMed Disclaimer

Comment on

References

    1. Bonaventure P, Shelton J, Yun S, Nepomuceno D, Sutton S, Aluisio L, Fraser I, Lord B, Shoblock J, Welty N, Chaplan SR, Aguilar Z, Halter R, Ndifor A, Koudriakova T, Rizzolio M, Letavic M, Carruthers NI, Lovenberg T, Dugovic C (2015) Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia. J Pharmacol Exp Ther 354:471–482. - PubMed
    1. Bradley AJ, Webb-Mitchell R, Hazu A, Slater N, Middleton B, Gallagher P, McAllister-Williams H, Anderson KN (2017) Sleep and circadian rhythm disturbance in bipolar disorder. Psychol Med 47:1678–1689. - PubMed
    1. Cepeda MS, Kern DM, Canuso CM (2021) At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: learnings from a population based study. Depress Anxiety 38:521–527. - PMC - PubMed
    1. Chung F, Abdullah HR, Liao P (2016) STOP-Bang Questionnaire: a practical approach to screen for obstructive sleep apnea. Chest 149:631–638. - PubMed
    1. Citrome L (2020) Food and Drug Administration-approved treatments for acute bipolar depression: what we have and what we need. J Clin Psychopharmacol 40:334–338. - PubMed